Zenosense, Inc. (OTCQB:ZENO) - Breaking News - September 5, 2018

Zenosense, Inc.: MIDS Medical JV to Receive Funding of up to $1.2million

VALENCIA, SPAIN - September 5, 2018 -- Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce that its MIDS Medical Ltd. joint venture (“MML") has entered a staged funding for the next phase of development of MIDS Cardiac.

On 31 August, 2018 MML entered into an agreement with a third party investor for funding of up to an aggregate amount of $1,200,000 (“Agreement”). This funding is expected to cover the costs of the next crucial development phase of the MIDS Cardiac microfluidic test strip which aims to embody a high sensitivity (“HS”) troponin assay or a similar assay to prove the MIDS system on a live test.

As reported on June 19, 2018 the patented MIDS technology has successfully detected commercial assay beads at a level approximately four times better than the threshold advised by MML’s assay consultants as required for a HS troponin assay.

The next phase development plan includes;

- Design and create an active version of the MIDS microfluidic strip, including the closer integration of the MIDS magnetic sensors to improve the detection levels even further;
- In conjunction with a leading assay development Company contracted to MML design, develop and embody a live HS assay on the MIDS test strip;
- Refinements of electronic circuitry and software, system testing and data collection; and
- The creation of compliance dossier.

MML’s work is ongoing and it plans to expand its development operations by engaging a number of specialists in the fields of electronics, microfluidics and software development to carry out the work required.

The outcome of this next phase is intended to prove to industry that the MIDS magnetic detection method can detect and accurately quantify a live HS assay on the MIDS microfluidic test strip. If successfully completed, the Company believes this will demonstrate that MIDS Cardiac can be used at the Point of Care for HS Troponin testing and is ready for final device development.

HS Troponin testing for myocardial infarction at the Point of Care would meet a critical unmet medical need. It is expected to be of intense interest to global diagnostic majors and the proof of concept should also open up substantial opportunities for the MIDS system to be applied to numerous other immunoassay tests.

Under the Agreement MML will receive an initial aggregate amount of $300,000 in exchange for ordinary shares in MML representing a 2.91% equity ownership, with the option to make scheduled payments up to an additional $900,000. The full $1,200,000 investment would equate to a final 10.31% equity ownership in MML.

Details of the Agreement have been filed on form 8K with the Securities and Exchange Commission.

About Zenosense, Inc.

Zenosense Inc., through a joint-venture ownership in MIDS Medical Ltd., is primarily focused on the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac. MIDS Medical applies patent-protected magnetic nanoparticle detection technology and a development team with world-class technical expertise. The MIDS Cardiac device and test strip is being designed to support a variety of rapid high sensitivity cardiac biomarker tests, with a focus on troponin I and T, to identify or discount Acute Myocardial Infarction with accuracy equal or superior to high sensitivity assays performed on laboratory analyzers. To find out more about Zenosense, visit www.zenosense.com

Forward-Looking Statements
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects,” "intends,” "plans,” "may,” "could,” "should,” "anticipates,” "likely,” "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed on filed on April 17, 2018, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Respective statements concerning the development of both MIDS Cardiac™ and other devices under development have been made based on information obtained from MIDS Medical Ltd., which the Company believes to be accurate, but have not been independently verified.

Contact:
Zenosense, Inc.
www.zenosense.com
Tel: +34 960 454 202
ir@zenosense.net
Source: Zenosense, Inc.

Zenosense Trading on the OTCQB Venture Market

VALENCIA, SPAIN, July 10, 2018 -- Zenosense, Inc. (OTCQB: ZENO) ("Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held device for the early detection of heart attack at the Point of Care, is pleased to announce that the Company is now trading on the OTC Markets Group OTCQB “Venture Market”.

Investors can find current financial disclosure, company news and Real-Time Level 2 quotes for Zenosense at: http://www.otcmarkets.com/stock/ZENO/quote

The OTCQB is recognized as an Established Public Market by the U.S. Securities and Exchange Commission and is a leading market for entrepreneurial and development stage U.S. and international companies.

To be eligible, companies must be current in their financial reporting, pass a minimum bid price test, and undergo an annual company verification and management certification process. The OTCQB Venture Market quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors. As a verified market with efficient access to U.S. investors, OTCQB helps companies build shareholder value with a goal of enhancing liquidity and achieving fair valuation.

About Zenosense, Inc.

Zenosense Inc., through a joint-venture ownership in MIDS Medical Ltd., is primarily focused on the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac. MIDS Medical applies patent-protected magnetic nanoparticle detection technology and a development team with world-class technical expertise. The MIDS Cardiac device and test strip is being designed to support a variety of rapid high sensitivity cardiac biomarker tests, with a focus on troponin I and T, to identify or discount Acute Myocardial Infarction with accuracy equal or superior to high sensitivity assays performed on laboratory analyzers. To find out more about Zenosense, visit www.Zenosense.com

Forward-Looking Statements

Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects,” "intends,” "plans,” "may,” "could,” "should,” "anticipates,” "likely,” "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed on filed on April 17, 2018, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Respective statements concerning the development of both MIDS Cardiac™ and other devices under development have been made based on information obtained from MIDS Medical Ltd. and Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.

Contact:
Zenosense, Inc.
www.zenosense.com
Tel: +34 960 454 202
ir@zenosense.net
Source: Zenosense, Inc.

Diagnostics Play Critical Role in Medical Sector


New York, NY – June 26, 2018 – NetworkNewsWire.com News Coverage:  Diagnostic devices are a crucial part of the medical technology sector, and many companies are pressing forward with work in this area. Zenosense, Inc. (OTC:ZENO) has just announced breakthrough quantitative test results for its MIDS Cardiac handheld diagnostic technology, under development to provide rapid cardiac biomarker tests in emergency settings. Thermo Fisher Scientific, Inc. (NYSE:TMO) has developed devices to streamline protein characterization, improve analysis of small molecules, and improve the speed and confidence of laboratory spectrometry. Merit Medical Systems, Inc. (NASDAQ:MMSI) has recently finalized a deal with NinePoint Medical that will increase access to NinePoint’s groundbreaking platform for the detection of esophageal cancer. Abbott Laboratories (NYSE:ABT) has undertaken the U.S. launch of an analyzer to help diabetics diagnose their state of health. And Koninklijke Philips N.V. (NYSE:PHG) has acquired Remote Diagnostic Technologies to increase its offering of frontline diagnostic tools, which include invaluable devices for emergency medicine.

Identifying the Problem

Diagnostic devices may not seem like one of the most glamorous aspects of medicine, but they are among the most important. They allow medical professionals to identify the ailments of patients and provide patients with the right treatment. Without accurate diagnosis, the whole process falls apart.

This importance has led to the growth of an increasingly buoyant market in diagnostic devices driven by cutting-edge technological innovations. From handheld devices that can be used anywhere to sophisticated, highly complex machines used in hospitals by skilled operators, diagnostic technologies form a market worth billions of dollars each year. Few devices or analyzers are perfect, especially regarding speed and ease of use. New technologies that advance diagnostic sensitivity and accuracy, reduce costs or make diagnosis more simple are in great demand. Each step forward brings improvements in clinical care and a chance for innovative companies to enter the market by offering advantages over established technologies, especially at the point of care (POC).

Improving Detection for Better Cardiac Care

Zenosense, Inc. (OTC:ZENO) recently announced breakthrough quantitative testing results of its MIDS Cardiac technology platform.

Developed by the Company’s MIDS Medical Limited joint venture (MML) based at the prestigious Sci-Tech Daresbury campus in the United Kingdom, MIDS Cardiac is a handheld POC technology for the detection of heart attack. It is designed to help medical staff rapidly diagnose heart attack at an early stage and so to improve treatment. By the early detection of certain cardiac event biomarkers, MIDS Cardiac is expected to significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain suspected as symptomatic of a heart attack.

Heart disease is the leading killer in the western world. In Europe and the United States alone, 15 to 20 million patients a year visit the emergency departments of hospitals reporting chest pain that could be a sign of an acute myocardial infarction, commonly referred to as a heart attack.

Swift diagnosis helps patients who are suffering from a heart attack as well as those who aren’t. It allows those with heart problems to receive the treatment they need. It also saves others from inappropriate and costly interventions. Like any good diagnostic tool, it can save lives and save money that hospitals need for other treatments.

MIDS Cardiac is designed to be just such a solution. The advantage of the MIDS technology lies in its superior detection technology and applying it to established immunoassay tests, with the first target being troponin.

MIDS goes beyond the optical technology used by most immunoassay tests. The analytical sensitivity gap between central laboratory testing platforms and existing POC testing devices is significant as this bulky optical technology has not been successfully miniaturized into high sensitivity capable, handheld devices. In contrast, the MIDS technology uses highly sensitive, custom-built “Hall Effect” magnetic sensors that allow it to detect extremely low levels of magnetic field disturbance caused by immunoassay beads. As the recent results indicate, this is expected to deliver Gold Standard, true high-sensitivity laboratory testing at the POC with results available in minutes — enabling high-sensitivity laboratory accuracy in emergency settings for the first time.

Breakthrough Quantitative Results

Early detection of heart attack by measuring very low levels of troponin released in the early stages of a heart attack is a vital unmet medical need at the POC. Key to the MIDS proposition is its highly portable, high-sensitivity ability to detect very low numbers of the microscopic paramagnetic beads commonly used in immunoassay tests and bound to these low levels of troponin.

Testing of MIDS has been underway since last year at MML’s facility at Sci-Tech Daresbury, United Kingdom. The nano-magnetic detection system and analytical electronics have been tested to gain a better understanding of how the system functions and how sensitive it is.

By running tests on different sets of beads, MML developers have been able to refine the nano-magnetic signal and filter out electronic noise to increase the sensitivity of the technology. Further testing has demonstrated the effectiveness of the improving system. While last year’s tests were successful, the recent quantitative results are even more impressive:

Using its revised magnetic and electronics technology, MIDS was able to detect the lowest quantities of beads to date (numbers confirmed by an independent study conducted by the University of Liverpool). Around 200,000 beads or less must be detected to service a high-sensitivity troponin test. MML’s quantitative testing results demonstrate that the MIDS technology can already detect as low as 50,000 beads.

The next steps are now to apply this groundbreaking technology to established assay techniques used in conventional laboratory analyzers to deliver state-of-the-art laboratory standard, high-sensitivity cardiac troponin testing at the POC.

Improving Point of Care Devices

The introduction of accurate handheld devices such as MIDS Cardiac is an important step for the POC market. Many of the most effective detection systems are too large and unwieldy to be used at the POC. Meanwhile, the handheld devices available for POC assessment lack the accuracy and reliability to definitively exclude the possibility of a cardiac condition. By miniaturizing laboratory-style and accuracy testing, Zenosense hopes to provide detection that is rapid, reliable and easily usable on the front line of medical care.

While this is a mission that will save lives, it is also one that could potentially bring the company a tidy profit. Medical sensors have been a top performer within the medical technology market for the past five years, performing even better than biotech. The global market for cardiac biomarker diagnostic tests alone is expected to reach a value of $7.2 billion this year, with $1.16 billion of that projected value in POC devices. MIDS therefore has the potential to tap into a valuable and growing market sector.

As Carlos Gil, CEO of Zenosense, said: “These results should not be underestimated. I am not aware of any other detection technology suitable for use at the POC, which comes anywhere close to achieving these results. . . . I truly believe we have a blockbuster technology in the making.”

Medical Technology Booms

Demand for ever-improving medical care has fueled the growth of many companies providing equipment and support for medical professionals.

Thermo Fisher Scientific, Inc. (NYSE:TMO) provides innovative technologies to support both patient diagnostics and medical research. The company showed off some of its latest advances at the 66^th Annual American Society for Mass Spectrometry conference earlier this month. There, it displayed devices built to streamline protein characterization, improve analysis of small molecules, and improve the speed and confidence of spectrometry work in food and environmental laboratories.

Like Thermo Fisher, Merit Medical Systems, Inc. (NASDAQ:MMSI) aims to innovate in medical devices and services. By focusing on customer needs, the company has created a diverse range of products that improve patients’ lives around the world. It has recently entered into a worldwide distribution agreement and strategic alliance with NinePoint Medical. This will provide Merit customers with access to NinePoint’s groundbreaking Optical Coherence Tomography platform, an invaluable tool in the detection of esophageal cancer. Successes like this led the company to record revenues in the first quarter of 2018.

With more than 125 years of experience behind it, Abbott Laboratories (NYSE:ABT) continues to be an important player in the medical technology field. The recent U.S. launch of its Afinion 2 analyzer provides a fast-working multi-assay platform that gives diabetics information about their state of health. It can be used in a wide variety of medical settings to give quick results and so allow patients to be analyzed and to discuss their results with a professional in a single visit. The latest generation of the company’s XIENCE heart stent has also recently been approved for use in the United States, and will provide better treatment for patients suffering from coronary artery disease.

Koninklijke Philips N.V. (NYSE:PHG), already a global leader in health technology, has recently acquired U.K.-based company Remote Diagnostic Technologies (RDT). This adds a comprehensive portfolio of emergency care solutions to Philips’ therapeutic care business, strengthening its position in the resuscitation and emergency care field and increasing its ability to drive change and enter new markets. The company already offers external defibrillators, advanced life support monitors and data management solutions, helping emergency teams to diagnose patients and provide them with the best in emergency care. With the addition of RDT’s range of diagnostic tools, the company’s position has become even stronger.

Diagnostic devices are a vital part of the medical technology sector. As they become more portable and more accurate, they help doctors to save lives and improve patients’ chances of survival, while simultaneously supporting the growth of influential medical tech companies.

For more information about Zenosense, please visit Zenosense, Inc. (OTC:ZENO)

 About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.

NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW and FNM undertake no obligation to update such statements.

NetworkNewsWire (NNW) is affiliated with the Investor Brand Network (IBN).

About IBN

Over the past 10+ years we have consistently introduced new network brands, each specifically designed to fulfil the unique needs of our growing client base and services. Today, we continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Please feel free to visit the Investor Brand Network (IBN) www.InvestorBrandNetwork.com

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com 
212.418.1217 Office
Editor@NetworkNewsWire.com   

Media Contact:
FN Media Group, LLC
NNW@FinancialNewsMedia.com  
+1-(954)345-0611

SOURCE:  NetworkNewsWire

Zenosense, Inc.: Breakthrough Quantitative MIDS Testing Results

VALENCIA, SPAIN, June 19, 2018 -- Zenosense, Inc. (OTCPK: ZENO) ("Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce that its MIDS Medical Ltd. joint venture ("MML") has successfully completed a second testing round of its revised detection system.

In 2017 the first next generation troponin assay for the early diagnosis of heart attack was approved for use in the U.S. by the FDA. High sensitivity (“HS”) troponin assays have been in use in other parts of the world for over 7 years. These assays are performed on state of the art central laboratory analyzers, which are expensive and typically take about an hour to turnaround results, when minutes are vital. The key to the MIDS technology is its ground breaking ability to magnetically detect and measure diagnostic assay beads in low enough numbers to support a HS troponin assay. MML aims to embody this highly compact technology into an easy to use, hand-held MIDS Cardiac device for rapid diagnosis in emergency rooms, or by paramedics responding to chest pain patients at the scene.

Highlights:

• Extensive revision and improvements to core Hall effect sensor electronics during H1 2018

• Testing on new electronics which confirms and materially improves upon the testing results announced in late 2017, with a near doubling of sensitivity

• Results achieved using two leading brands of commercially available assay beads

• Assay bead numbers detected are well within the Limit of Detection (“LoD”) required for a HS troponin assay

2018 Quantitative Testing Results

Quantitative testing was conducted to (a) determine the minimum number of assay beads that can be detected; and (b) to prove linearity of detection signal to quantified bead numbers. MML has been advised by Future Diagnostics Solutions B.V. (a leading assay developer engaged to MML) that a capability to detect below 200,000 assay beads and preferably less than 110,000 is required to support a HS troponin test.

Two brands of beads were tested: GE Sera-Mag™ (3μm) and Thermo Fisher Scientific M-270 Dynabeads® (2.8 μm), both of which are regarded as suitable for a HS troponin assay and have similar paramagnetic characteristics.

The MIDS LoD of both these brands was seen on a reliable, repeatable basis at around 50,000 beads, with good signal linearity (required for accurate assay quantitation) at higher numbers. This number of beads detected at the LoD is approximately four times lower than the maximum threshold and therefore well within the range advised by Future Diagnostics as suitable for a HS troponin assay.

MML Managing Director and Chief Scientific Officer Dr. Nasser Djennati commented: “MIDS is a hugely challenging development. The results of this second round of testing are quite extraordinary, as magnetic detection at this level for this application is unheard of. We can now move forward and apply the MIDS detection to established assay techniques used in conventional analyzers as we seek to deliver state-of-the-art laboratory standard, high sensitivity cardiac troponin testing at the Point of Care.”

Improved Electronics

MML has revised its core Hall Effect sensor electronics during the first half of 2018 to further enhance the ability of MIDS to detect and accurately quantitate the nano-Tesla magnetic signal of the relatively low numbers of assay beads required for a HS troponin assay.

MML estimates that compared to the previous electronics, the sensitivity of the platform has been improved by a factor of nearly 2, as well as materially improving its stability.

Independent, Third-Party SEM Verification of Bead Numbers

MML has carried out an in-house Scanning Electron Microscope investigation (“MML SEM”) and has received a confirmatory study carried out by the Condensed Matter Physics group and Materials Innovation Factory at the Department of Physics of the University of Liverpool (“Liverpool SEM”). The MML SEM and Liverpool SEM indicate that a maximum of around 92,000 beads (Liverpool SEM) were previously detected at the LoD in 2017.

The recent quantitative testing on the improved electronics has demonstrated a substantial improvement on the initial testing results, now indicating that approximately 50,000 beads of a type suitable for a HS troponin assay can be detected at the LoD.

The Company is delighted that the achieved detection of around 50,000 beads is already considerably lower than the maximum number suitable for a HS troponin assay. It is confident that a further material reduction to this number at the LoD can be achieved when unpackaged Hall effect sensors are used as planned in a production lab-on-chip test strip.

Next Steps

MML is now planning the next key phase of development to test microfluidic detection on the revised electronics platform and to embody a HS assay on a test strip.

Carlos Gil, CEO of Zenosense, commented: “These results should not be underestimated. I am not aware of any other detection technology suitable for use at the Point of Care which comes anywhere close to achieving these results. We are now so far within the limit of detection I am extremely confident that high sensitivity rapid troponin testing can become a reality in emergency settings. Achieving these results is a huge step towards that. I truly believe we have a blockbuster technology in the making.”

Dr. Dave Dekkers, Scientist at Future Diagnostics Solutions B.V. said: “We are impressed by the achievement of MIDS Medical Ltd. for the detection of 50,000 beads with their Biosensor. Future Diagnostics will follow MML closely on their progress with the further development of this sensor.”

About Zenosense, Inc.
Zenosense Inc., through a joint-venture ownership in MIDS Medical Ltd., is primarily focused on the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac. MIDS Medical applies patent-protected magnetic nanoparticle detection technology and a development team with world-class technical expertise. The MIDS Cardiac device and test strip is being designed to support a variety of rapid high sensitivity cardiac biomarker tests, with a focus on troponin I and T, to identify or discount Acute Myocardial Infarction with accuracy equal or superior to high sensitivity assays performed on laboratory analyzers. To find out more about Zenosense, visit www.Zenosense.com

Forward-Looking Statements
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects,” "intends,” "plans,” "may,” "could,” "should,” "anticipates,” "likely,” "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed on filed on April 17, 2018, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Respective statements concerning the development of both MIDS Cardiac™ and other devices under development have been made based on information obtained from MIDS Medical Ltd. and Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.

Contact:

Zenosense, Inc.
www.zenosense.com
Tel: +34 960 454 202
ir@zenosense.net

Source: Zenosense, Inc.

Zenosense, Inc.: MIDS Shareholder Update

VALENCIA, SPAIN, May 24, 2018 -- Zenosense, Inc. (OTCPK: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care handheld device for the early detection of certain cardiac event biomarkers. We believe that MIDS Cardiac will significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain symptomatic of acute myocardial infarction (heart attack). The MIDS Cardiac development is being carried out by our MIDS Medical Limited joint venture ("MML") based at Sci-Tech, Daresbury (UK).

The Company notes the recent decline in its share price and knows of no operational reason for this. The development by MML of the MIDS technology platform is progressing as planned. Within the next few weeks the Company expects to receive the following development information from MML:

A summary of revisions and enhancements to the core MIDS electronics as a result of research and development work carried out by MML during the latter part of 2017 and to date in 2018. These enhancements are expected to deliver a material improvement in the MIDS platform capability in respect of the sensitivity and reproducibility of assay bead detection.
Results from tests using the revised electronics to be carried out on two brands of commercially available composite assay beads of a type believed to be suitable for a high sensitivity troponin assay.
These quantitative results will include definitive numerical estimates of the numbers of assay beads that have been detected, verified by a qualified and independent third party, so that the diagnostic industry can be better informed of the MIDS capability.
A further update will be issued in due course on receipt of the above information.

About Zenosense, Inc.

Zenosense Inc.'s primary focus, through our joint venture ownership in MIDS Medical Ltd., is the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac™, and is also the holder of an exclusive global license agreement to develop and market effective medical devices for use in hospitals and primary healthcare settings targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients.

To find out more about Zenosense (OTC PINK: ZENO), visit our website at www.zenosense.com.
 
Forward-Looking Statements
Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties. Forward-looking statements can often be identified by words such as "expects,” "intends,” "plans,” "may,” "could,” "should,” "anticipates,” "likely,” "believes" and words of similar import. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company. Readers are cautioned not to place undue reliance on such forward-looking statements. Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed on filed on April 17, 2018, and in Company reports filed subsequently thereto. Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Respective statements concerning the development of both MIDS Cardiac™ and other devices under developmenthave been made based on information obtained from MIDS Medical Ltd. and Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.

Contact:
Zenosense, Inc.
Email: ir@zenosense.net
Tel: +34 960 454 202
Web: www.zenosense.com

Source: Zenosense, Inc.

-------------------------------------------------------------------
About Zenosense, Inc.:

The Revolution in Cardiac Diagnostics

Zenosense, Inc. (OTC:ZENO) participates in the development of transformational medical diagnostic technologies: hand-held devices used at the Point of Care replacing slow and expensive laboratory testing. Our core focus through our joint venture in MIDS Medical (http://midsmed.com/) is the development and commercialisation of MIDS Cardiac™. A hand held device being developed for use at the Point of Care for the rapid testing of cardiac markers delivering results equal or superior to laboratory gold standard accuracy within minutes. A device which can revolutionize the diagnosis and management of suspected Acute Myocardial Infarction (AMI).

Our team of professionals has world class expertise and technical know-how of the application of highly specific nano magnetic particle technology to medical testing. This knowledge, alongside their commercial experience of the Point of Care market, puts MIDS Medical in an excellent position to commercialise MIDS Cardiac™ and become the leading innovator in this field.

Laboratory
The MIDS Medical laboratory is located at the prestigious, UK Government supported Sci-Tech Daresbury campus in the UK. Sci-Tech Daresbury is internationally recognised for leading-edge scientific research and commercial development.

Cardiovascular disease is the leading cause of death in the Western World
> Accounting for more than 17 million deaths p.a. In Europe and the US alone approximately 15-20 million patients a year visit an
> Emergency Department (ED) reporting chest pain which must be investigated as possibly caused by a cardiac event.

Acute Myocardial Infarction (heart attack, Acute Myocardial Infraction “AMI”) affects all of us at some point in our lives, directly or indirectly, Rapid diagnosis is key; treatment in the first “Golden Hour” being crucial to survival. Equally, early “rule out” of AMI as the cause of chest pain can save healthcare providers $billions.

TECHNOLOGY

Immunoassay tests are commonly used to diagnose a whole host of disease / medical conditions. In general the technology behind them relies on the manipulation of magnetic nanoparticles. However laboratory and Point of Care tests generally use optical technology to detect these particles; only around 30% of particles can be detected in this way, severely limiting accuracy.

Where others finish up, we start detecting. To a whole new level of accuracy: The MIDS patented technology not only uses a bespoke optical sensor like other devices, but also utilizes miniaturised, highly sensitive custom built “Hall Effect” magnetic sensors embedded within a test strip as a Lab-On-Chip device. This patented technology can detect extremely low levels (nano-Tesla) of magnetic field disturbance caused by discrete test particles; In simple terms, instead of optically reading “clumps of particles” by standard methods, magnetically identifying the signature of discrete particles is expected to produce a substantially more accurate test result within minutes. A rapid test system that accurately measures troponin I and T and other key cardiac markers is, we believe, a blockbuster technology. It should be a “Must Have” for global diagnostic companies.

Market Opportunity
The global market for cardiac biomarker diagnostic tests is projected to reach $7.2 billion by 2018, of which $1.16 billion is expected to be served by Point of Care devices. The Point of Care market is in its infancy; existing Point of Care hand held devices are not accurate or reliable enough to definitively exclude AMI. Our ultimate goal is to match or exceed current “Gold Standard” high-sensitivity cardiac assays, currently carried out on relatively slow, hugely expensive laboratory analyzers. One multinational diagnostic company claiming the highest levels of accuracy on the market for a Point of Care cardiac marker device in reality achieves a mere 65% sensitivity (correctly identifying the condition).

This poor sensitivity comes nowhere near what we expect MIDS Cardiac™ device to achieve. And despite the shortcomings of Point of Care cardiac devices currently on the market, 100’s of millions of dollars per year are generated from device and strip sales to simply aid the diagnosis of AMI in conjunction with ECG and clinical symptoms. We are confident that our technology platform will deliver unparalleled levels of accuracy, speed, reliability, ease of use and cost savings which will make it the device of choice for hospitals, ERs, family practitioners, paramedics and low resource settings. It is no wonder the MIDS technology is already attracting interest from a number of the global majors.

The Future
Cardiac is just the first MIDS application. The MIDS technology platform could be adapted to a vast array of Point of Care immunoassay tests, taking them to a whole new level of accuracy, cost, ease of use and speed of testing: A multi-capability Point of Care device with laboratory “Gold Standard” accuracy for testing for conditions such as Chlamydia, prostate, colorectal and other cancers, stroke tests, sports anti-doping tests, Drugs of Abuse, insulin tests, H. Pylori, Inflammatory & Autoimmune disease, Influenza, Legionella, Osteoporosis, Endocrine tests, Respiratory Virus, pneumonia, Blood infections, Streptococcus, Meningitis, Rheumatism, Hepatitis, HIV, Viral tests, and many more. These common medical tests are performed all day long at huge expense in medical testing laboratories worldwide, in a market projected to be worth $23.7 billion per year worldwide by 2019.

A successful development of MIDS Cardiac™ is expected to be the first step in the development of technology platform which can serve a whole host of these other critical tests. The MIDS technology super-accurate quantitation, applicable to a new generation of High Sensitivity medical tests, could be the most significant advance in decades, representing the Holy Grail of diagnostic testing.

Our development team has:

> World class expertise in the field of quantitative micro-magnetic and luminescence measurement techniques and applying that specialism to measure density and behavior of particulate markers within body fluids.
> Thirty years cumulative experience in magnetic measurement and magnetic sensor (Hall Effect and Bio-Sensors) design and specifically in magnetic nano-particle applications within the medical and bio-engineering Point of Care field.
> High level experience of dealing with the measurement of changes within body fluids and tissues in micro and nano environments.
> Extensive experience in the design and development of small, low cost Point of Care measurement devices that read changes occurring on input strips, from an engineering, physics (optics and magnetic), reader software and end user perspective.
> Clear understanding of quality standards, timescales, processes and testing rigours required in the Point of Care healthcare area.
> Established relationships with commercial partners capable of creating license revenue for enhancements of existing market products and to develop multiple new revenue streams from new applications.
> A broad skills base across its management team covering scientific, technical and financial expertise. Team members have experience of closing deals related to products in this sector.

SOURCE: http://www.zenosense.com/

Disclaimer